7. (Amended) The AAV Rep78 mutant of claim 6, wherein said AAV Rep78 modified protein is a truncated AAV Rep78 protein containing at least the minimum number of amino acids of the wild-type AAV Rep78 protein necessary to bind to said DNA sequence to obtain enhanced inhibition of a papillomavirus or an oncogene.

9. (Amended) The AAV Rep78 mutant of claim 8, wherein said papillomavirus promoter region is nucleotides 14-56 of p97 of HPV-16 of SEQ ID NO:4.

13. (Amended) A fusion protein comprising a wild-type AAV Rep78 protein or an AAV Rep78 modified protein that binds to at least one DNA sequence obtained from one or more of a papillomavirus, an AAV, an oncogene or a HIV differently as compared to the binding of said wild-type AAV Rep78 protein, and that results in AAV DNA replication and/or AAV virion production.

19. (Amended) A pharmaceutical composition comprising at least one AAV Rep78 mutant according to claim 2 or an AAV Rep 78 protein, in admixture with a pharmaceutically acceptable carrier.

Kindly add the following claims:

46. (NEW) The AAV Rep78 mutant of claim 2 wherein said binding results in AAV DNA replication and/or AAV virion production.

47. (NEW) The fusion protein of claim 13, wherein said different DNA binding is selected from the group consisting of no DNA binding, weak DNA binding and enhanced DNA binding as compared to the binding of a wild-type AAV Rep78 protein.

REMARKS

Claims 2-20, 46 and 47 are pending. Claims 21-45 are canceled without prejudice or disclaimer as directed to non-elected claims for filing in at least one or more divisional applications. Claim 1 is canceled to more clearly define the present invention, and should not be construed as the surrender this subject matter. Applicants reserve the right to pursue any